In the latest from PM360, Lisa Micarelli, Director of Strategy at McCann Health Managed Markets, explores how payer strategies, such as the healthcare provisions of the 2022 Inflation Reduction Act, will impact drug pricing in the US.
“We are at the precipice of significant pricing change in the pharmaceutical industry with these cost control mechanisms shaping the future landscape of drug prices and affordability across markets,” Lisa said. “We must strive to balance these cost-control pressures to ensure we don’t stifle opportunities for continued innovation in healthcare.”
